

Remarks

Original claims 1-10 have now been replaced by new claims 11-22, limited to the compounds of the general formula (I), where R¹ as defined in group (A), is no longer “benzo[1,3]dioxolyl”, R¹ as defined in group (B), is no longer “heterocyclyl”, R² is substituted phenyl, R³ and R⁴ are each hydrogen, Q is absent and m is 0.

An obvious typing error has been corrected in claim 6 (new claim 16), where, based on the disclosure on page 18, line 5 from the bottom, “hydrogen” has been replaced by “oxygen” in the definition of X.

A new claim 18 has been added, directed to two intermediates which are disclosed, for example, in Example 2 on page 25 in paragraphs b) and c).

The reference to a pharmaceutically inert excipient in new claim 19, corresponding to original claim 9, is supported by page 20, line 5 from the bottom of the specification.

New claims 20 and 21 correspond to original claims 10 and 11, respectively, except that the so-called “use” format of these claims has been avoided.


New claim 22 is directed to the preferred embodiments in original claim 11.

Applicants emphasize that the amendments to the claims are without prejudice to their rights to file a continuing application for the subject matter which has been deleted from the claims.

Respectfully submitted,

Peter HEROLD et al.

By:



Michael R. Davis
Registration No. 25,134
Attorney for Applicants

MRD/pth
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
February 4, 2008